CJ
Therapeutic Areas
Exelixis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cabozantinib | Advanced Renal Cell Carcinoma | Phase 3 |
| Zanzalintinib + atezolizumab | Metastatic Colorectal Cancer | Phase 3 |
| Zanzalintinib + nivolumab | Non-Clear Cell Renal Cell Carcinoma | Phase 3 |
| Zanzalintinib | Neuroendocrine Tumors | Phase 2/3 |
| Zanzalintinib + belzutifan | Renal Cell Carcinoma | Phase 3 |
| XL309 | Multiple Solid Tumors | Phase 1 |
| XB010 | Multiple Solid Tumors | Phase 1 |
| XB628 | Multiple Solid Tumors | Phase 1 |
Leadership Team at Exelixis
MM
Michael M. Morrissey
President and Chief Executive Officer
DT
Dana T. Aftab
Executive Vice President, Research and Development
BJ
Brenda J. Hefti
Senior Vice President and General Counsel
PH
P.J. Haley
Executive Vice President, Commercial
SP
Stelios Papadopoulos
Chair of the Board
MC
Mary C. Beckerle
Director
SG
S. Gail Eckhardt
Director
MC
Maria C. Freire
Director
T(
Tomas (Tom) J. Heyman
Director
DE
David E. Johnson
Director